All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Impact of leukemic molecular profile on the efficacy of inotuzumab ozogamicin in R/R ALL
Bookmark this article
|
Results from the phase III INO-VATE (NCT01564784) trial evaluating the efficacy of inotuzumab ozogamicin (InO) for the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL) were published in Blood Advances by Zhao et al.1 Responses to InO were recorded in 91 patients by leukemic subtype, genomic alterations, and risk status.
|
| Key learnings |
|
The median overall survival was 7.7 months with InO compared with 6.2 months with standard of care (SoC) chemotherapy (hazard ratio, 0.75; p = 0.0105). |
|
Patients with high-risk molecular profiles experienced improved complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates with InO compared with SoC chemotherapy (74.7% vs 33.3%; p < 0.001).
|
|
The CR rate in patients with TP53 alterations was also higher with InO compared with SoC chemotherapy (100% vs 12.5%; p = 0.0047). |
|
The findings from the study suggest that InO may be a viable option for patients with R/R ALL, particularly those with high-risk molecular profiles, offering personalized treatment strategies. Further exploration of InO efficacy is needed in patients with BCR::ABL1-like subtype and TP53 alterations.
|
- Zhao Y, Laird A, Roberts K, et al. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Advances. 2024;8(12):3226-3236. DOI: 1182/bloodadvances.2023012430
Your opinion matters
13 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox